b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Data-Review" Owner="NLM">\n        <PMID Version="1">32056716</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>02</Month>\n            <Day>19</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1096-0341</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>541</Volume>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>Feb</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Virology</Title>\n                <ISOAbbreviation>Virology</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>MiR-BART1-5p targets core 2\xce\xb2-1,6-acetylglucosaminyltransferase GCNT3 to inhibit cell proliferation and migration in EBV-associated gastric cancer.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>63-74</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="pii" ValidYN="Y">S0042-6822(19)30346-0</ELocationID>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.virol.2019.12.004</ELocationID>\n            <Abstract>\n                <AbstractText>GCNT3 (core 2\xce\xb2-1,6-acetylglucosaminyltransferase) is a novel core mucin synthase. It is known that abnormal expression of GCNT3 promotes the progression of several human cancers. However, its relationship with Epstein-Barr virus (EBV) has not been comprehensively studied. We found GCNT3 expression in EBV-associated gastric cancer cells and tissues to be lower than in EBV-negative gastric cancer cells and tissues, and high expression was significantly associated with advanced tumor-lymph node metastasis. Luciferase reporter assay revealed that miR-BART1-5p directly targeted GCNT3. In addition, miR-BART1-5p mimics transfection was observed to reduce cell proliferation and migration, while miR-BART1-5p inhibitor increased cell proliferation and migration following transfection. In conclusion, both miR-BART1-5p and knockdown of GCNT3 inhibited cell proliferation and migration. In addition, EBV may regulate GCNT3 by affecting the NF-kB signaling pathway. E-cadherin, N-cadherin, vimentin, and p-ERK were found to be downstream molecules of the miR-BART1-5p/GCNT3 pathway.</AbstractText>\n                <CopyrightInformation>Copyright \xc2\xa9 2019 Elsevier Inc. All rights reserved.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Liu</LastName>\n                    <ForeName>Juanjuan</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathogenic Biology, Qingdao University Medical College, 38 Dengzhou Road, Qingdao, 266021, China. Electronic address: qdliujuanjuan@163.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhang</LastName>\n                    <ForeName>Yan</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathogenic Biology, Qingdao University Medical College, 38 Dengzhou Road, Qingdao, 266021, China; Department of Clinical Laboratory, Central Hospital of Zibo, 54 Gongqingtuan Road, Zibo, 255036, China. Electronic address: qdzhangyan01@163.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Liu</LastName>\n                    <ForeName>Wen</ForeName>\n                    <Initials>W</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathogenic Biology, Qingdao University Medical College, 38 Dengzhou Road, Qingdao, 266021, China. Electronic address: liu.wen@hotmail.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zhang</LastName>\n                    <ForeName>Qianqian</ForeName>\n                    <Initials>Q</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathogenic Biology, Qingdao University Medical College, 38 Dengzhou Road, Qingdao, 266021, China. Electronic address: qdzqqian@163.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Xiao</LastName>\n                    <ForeName>Hua</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathogenic Biology, Qingdao University Medical College, 38 Dengzhou Road, Qingdao, 266021, China. Electronic address: qdxhchris@163.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Song</LastName>\n                    <ForeName>Hui</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathogenic Biology, Qingdao University Medical College, 38 Dengzhou Road, Qingdao, 266021, China. Electronic address: qdsonghui1996@163.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Luo</LastName>\n                    <ForeName>Bing</ForeName>\n                    <Initials>B</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Pathogenic Biology, Qingdao University Medical College, 38 Dengzhou Road, Qingdao, 266021, China. Electronic address: qdluobing@163.com.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>12</Month>\n                <Day>11</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Virology</MedlineTA>\n            <NlmUniqueID>0110674</NlmUniqueID>\n            <ISSNLinking>0042-6822</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Core 2\xce\xb2-1,6-acetylglucosaminyltransferase</Keyword>\n            <Keyword MajorTopicYN="N">Epstein-Barr virus</Keyword>\n            <Keyword MajorTopicYN="N">Gastric carcinoma</Keyword>\n            <Keyword MajorTopicYN="N">miR-BART1-5p</Keyword>\n        </KeywordList>\n        <CoiStatement>Declaration of competing interest The authors declare no conflict of interest.</CoiStatement>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>10</Month>\n                <Day>08</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>22</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>12</Month>\n                <Day>10</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>15</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>15</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>15</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">32056716</ArticleId>\n            <ArticleId IdType="pii">S0042-6822(19)30346-0</ArticleId>\n            <ArticleId IdType="doi">10.1016/j.virol.2019.12.004</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'